EIN 94-3240841

Aids Vaccine Advocacy Coalition (AVAC)

IRS 501(c) type
501(c)(3)
Num. employees
36
Year formed
1995
Most recent tax filings
2022-12-01
NTEE code, primary
Description
AVAC is a New York City-based international non-profit community- and consumer-based organization working to accelerate ethical development and delivery of AIDS vaccines and other HIV prevention options to populations throughout the world.
Total revenues
$14,790,975
2022
Total expenses
$13,528,583
2022
Total assets
$7,187,054
2022
Num. employees
36
2022

Program areas at AVAC

Product introduction and access: the product introduction program is designed to identify and anticipate needs and gaps and provide targeted tools, support and platforms to expand access to hiv/aids prevention. The program focuses on: successful scale-up and introduction in three priority countries from the outset; develop adaptable and scalable tools to support other countries; support the development of marketable products in the hiv prevention and sexual and reproductive health research pipeline; and create a flexible mechanism to assist product developers, funders and country programs to identify and address barriers to improved products and accelerated introduction. Projects are implemented in collaboration with a network of funders, (continued on schedule o)continued: product developers and governmental and non-governmental organizations including the bill and melinda gates foundation, childrens investment fund foundation, world health organization, population council, viatris, mann global health, medicines360, usaid, catalyst global, hiv prevention trials network, and clinton health access initative.
Policy Advocacy: avac works with partners and policymakers to develop and pursue bold national, regional, and international agendas that advance hiv prevention and global health equity and lay a solid foundation for global health security against future pandemics. Avac helps to shape global health spending and planning for hiv prevention by mobilizing to ensure programs, products and policies are evidence-based, inclusive and effective. With a network of partners, avac identifies critical policy needs and develops strategic campaigns to advance hiv prevention with a focus on ensuring a rich r&d pipeline with rollout plans to reach affected communities. Avac and partners founded and support the global Aids policy partnership and federal Aids policy (continued on schedule o)continued: partnership to create diverse coalitions that work to maintain and expand well-resourced, evidence-based hiv prevention and treatment programming and funding at us and international levels. Through the compass program, avac works with partners to change the hiv response through high-impact, data-informed transnational Advocacy campaigns led by civil society organizations reprsenting communities most impacted by hiv. These campaigns increase civil society impact on hiv-related policies, programs and approaches to prevention.
Research engagement and preparedness: research preparedness is designed to shape the r&d environment through Advocacy for investment, political support, and good participatory practice. Avac tracks and translates both community Advocacy and complex science to make the science accessible and position community priorities at the center of global health. Avac improved trial design and conduct by bringing together researchers, trial site staff, civil society, policymakers, trial participants, and communities to center perspectives of affected communities in research. Avac developed materials and documents relating to the prevention of hiv/aids; convened multiple meetings with stakeholders such as researchers and civil society leaders to discuss research findings; (continued on schedule o)continued: supported Advocacy networks and major africa-led initatives to call for choice and equity in hiv prevention investments globally; and issued subgrants to more than 13 partners in the us and africa under the hiv biomedial prevention research project funded by usaid identify and mitigate or eliminate barriers to the development of and access to new hiv vaccines and other prevention options; and promote increased resources for hiv Vaccine and prevention research by donors including government agencies.
Programs are global movement and program management and coordination.

Grants made by AVAC

GranteeGrant descriptionAmount
International Aids Vaccine Initiative (IAVI)Hiv Vaccine and Biom$0
Fhi 360Hiv Vaccine and Biom$0
Aids Research Foundation or amfARTo Increase Adoption$0
...and 4 more grants made

Who funds Aids Vaccine Advocacy Coalition (AVAC)

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Bill & Melinda Gates FoundationHiv$3,300,000
Bill & Melinda Gates FoundationHiv$2,251,722
Fhi 360Hiv Related Research$782,151
...and 9 more grants received

Personnel at AVAC

NameTitleCompensation
Erin KiernonBoard Member$240,612
Abigail SmithChief Financial Officer$205,567
Mitchell WarrenBoard Member$380,391
David CookTreasurer / Board Member$0
Blair HanewallPresident / Board Member$0
...and 4 more key personnel

Financials for AVAC

RevenuesFYE 12/2022
Total grants, contributions, etc.$14,776,117
Program services$0
Investment income and dividends$14,271
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$587
Total revenues$14,790,975

Form 990s for AVAC

Fiscal year endingDate received by IRSFormPDF link
2022-122023-11-10990View PDF
2021-122022-11-11990View PDF
2020-122021-11-15990View PDF
2019-122021-03-31990View PDF
2018-122020-01-16990View PDF
...and 8 more Form 990s
Data update history
January 2, 2024
Posted financials
Added Form 990 for fiscal year 2022
January 2, 2024
Updated personnel
Identified 1 new personnel
December 28, 2023
Received grants
Identified 2 new grant, including a grant for $374,917 from New Venture Fund
December 25, 2023
Used new vendors
Identified 2 new vendors, including , and
October 14, 2023
Updated personnel
Identified 9 new personnel
Nonprofit Types
Social advocacy organizationsDisease-focused nonprofitsCharities
Issues
HealthHuman servicesDiseases and disordersHIV / AIDS
Characteristics
Political advocacyProvides grantsOperates internationallyState / local levelReceives government fundingCommunity engagement / volunteeringTax deductible donations
General information
Address
Ellenoff Grossm 1345 6th Ave FL11
New York, NY 10105
Metro area
New York-Newark-Jersey City, NY-NJ-PA
Website URL
avac.org/ 
Phone
(212) 796-6423
Facebook page
HIVpxresearch 
Twitter profile
@hivpxresearch 
IRS details
EIN
94-3240841
Fiscal year end
December
Taxreturn type
Form 990
Year formed
1995
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
G81: HIV / AIDS
NAICS code, primary
813319: Social Advocacy Organizations
Parent/child status
Independent
Free account sign-up

Want updates when AVAC has new information, or want to find more organizations like Aids Vaccine Advocacy Coalition (AVAC)?

Create free Cause IQ account